EPA approves Grignard Pure for use in Marlyand, Nevada, Pennsylvania and Texas.  - Luminator

EPA approves Grignard Pure for use in Marlyand, Nevada, Pennsylvania and Texas. 

Luminator

The U.S. Environmental Protection Agency (EPA) approved a Section 18 Public Health Emergency Exemption to use Grignard Pure for intrastate transportation and transit applications in Maryland, Nevada, Pennsylvania and Texas.

This antimicrobial air treatment solution allows for continuous protection against the virus that causes COVID-19, SARS-CoV-2.  It is proven to hill 98% of SARS-CoV-2 virus particles in the air. The solution will be administered through Luminator Technology Group’s Renew Air Treatment System.

The emergency protection was approved for use in Georgia and Tennessee earlier this year. It applies for use in occupied and unoccupied indoor spaces when public health guidelines are hard to maintain.

Grignard Pure helps protect passengers, operators and transit employees from the spread of SARS-CoV-2 in mass transit environments. The solution is dispensed on-board transit bus and rail vehicles through Luminator’s adaptive system.

“While we continue to learn about the characteristics of this virus, ensuring the public has access to the latest information and protections plays a critical role in the recovery of both our national and local economies,” said Etienne Grignard, co-founder and CEO of Grignard Pure. “The EPA approval of Grignard Pure allows entities in these states to deploy science-based technology solutions to enhance safety. Through this partnership with Luminator, it will help protect transit riders and operators.”

Luminator’s system adjusts the amount of Grignard Pure that is dispensed as conditions change. The system still kills 98% of COVID-19 airborne virus particles.

“Over the past fifteen months or so, those of us in public and environmental health have learned much about the properties and behaviors of the virus as we continue to develop and provide best practices for stopping the spread,” said Thomas Hodge, former CDC director of immunogenetics. “We know now with certainty that the virus is airborne, and an antimicrobial air treatment solution is needed to combat the virus particles. I’ve had the opportunity to work closely with the Grignard Pure team to assure the effectiveness of the solution can help society restore the social, cultural and business norms we enjoyed pre-pandemic.”

 

Originally posted on Metro Magazine

0 Comments